複合語候補ITC103

複合語スコア
heart failure11362.654529566
chronic heart failure519.90606666886
symptoms of heart failure513.21411655139
n engl j med390.00549803189
heart failure hospitalization356.42102496814
congestive heart failure280.57032391471
coronary artery disease277.15825556087
j am coll cardiol271.7851694969
iv heart failure224.04269055375
systolic heart failure187.10772077547
heart rate177.54273087838
severe heart failure171.42592868794
decompensated heart failure164.42484855543
ejection fraction164.27110467461
incident heart failure163.40050263775
et al153.3196976963
management of heart failure147.17527658401
diastolic heart failure147.17527658401
american heart association143.75766327291
acute decompensated heart failure143.51945164387
new-onset heart failure141.21630632987
heart failure society of america120.506594213
incidence of heart failure118.88245834328
heart disease115.51473789864
ace inhibitors104.12993381006
myocardial infarction97.141201813281
symptomatic heart failure95.180225031078
ventricular dysfunction91.927834917645
nyha class ii89.843380196645
advanced heart failure77.875396291055
diagnosis of heart failure76.36157006205
heart failure trial74.680896851249
valsartan heart failure trial69.316207802652
suspected heart failure68.030424883464
clinical heart failure67.671396040077
structural heart disease65.794994603193
development of heart failure64.845532444825
heart work61.502606079176
risk factors56.78140354932
increased risk55.130657644958
systolic dysfunction53.149688412681
treatment of heart failure52.64902149553
heart failure patients52.488256746022
history of heart failure49.058425528003
heart failure outcomes48.828628936152
prevention of heart failure48.828628936152
common cause of heart failure46.217324350561
diastolic dysfunction44.493513012808
accf/aha stages of heart failure43.933256091005
acute heart failure43.291703567625
ventricular hypertrophy42.556750670457
blood pressure40.912311036161
ace inhibitor40.465445621929
acute myocardial infarction39.157846511086
valvular heart disease39.07778423469
progression of heart failure38.937698145528
reduced ejection fraction38.279943609919
cardiac transplant38.088840897721
nyha class37.168436488375
systolic heart failure treatment36.624624147531
clinical trial36.514252915594
type of heart failure36.393324585865
end-stage heart failure36.393324585865
new heart failure36.393324585865
chronic systolic heart failure36.280570898978
heart failure hospitalizations35.304076582467
heart failure information35.304076582467
new york heart association35.161605961199
chronic heart failure therapy34.119607961832
heart failure exacerbations34.015212441732
mild heart failure34.015212441732
heart outcomes prevention evaluation32.550361330155
overt heart failure32.422766222413
refractory heart failure32.422766222413
standard medical therapy32.220500574413
comprehensive heart failure practice guideline30.512498229377
established heart failure30.30410916161
undiagnosed heart failure30.30410916161
preserved ejection fraction29.847191914672
primary symptoms of heart failure29.832302124903
current symptoms of heart failure29.396302199663
severe symptoms29.302732011878
chronic congestive heart failure29.232377228144
ventricular ejection fraction29.073272214158
nyha class ii heart failure28.730557789481
severe decompensated heart failure28.487192131714
butler j27.817093114978
functional cause of heart failure symptoms27.674153402284
high risk27.565328822479
severe chronic heart failure27.381589902864
coronary disease27.162114335027
nonischemic systolic heart failure27.139328065196
functional class27.089969968019
severe symptomatic heart failure25.624331641334
advanced chronic heart failure25.481440613546
non-ischemic systolic heart failure25.460562669705
severe congestive heart failure25.289070095955
renal function25.135581073296
primary cause of heart failure24.870462797164
stage c heart failure24.649903576842
all-cause mortality24.578701598965
pitt b23.905695622382
valsartan heart failure trial investigators23.623333128789
nyha class iii23.577076175429
eur heart j23.377254482009
long-term management of heart failure23.190179526877
left ventricular systolic dysfunction22.710284630869
ventricular pacing22.70333804263
african american heart failure trial22.64064168927
standard therapy22.62189070204
left ventricular dysfunction22.095958211392
family history of heart failure22.044116795314
health burden of heart failure21.8669953659
pulmonary artery pressure21.802122352441
cardiovascular death21.65736770668
myocardial ischemia21.502111138339
randomized trial of patients21.281414946154
population burden of heart failure21.265488388788
high blood pressure20.387204864274
borderline diastolic heart failure20.214544230179
physical activity19.991995195515
yusuf s19.817003712138
different stages of heart failure19.759060825555
african-american heart failure trial investigators19.74813326343
early evidence of heart failure19.589389217353
advanced end-stage heart failure19.500538833241
clinical trials19.364606884933
cases of incident heart failure19.215537915851
modifiable risk factors19.096568395957
heart catheterization19.078208021575
cardiovascular disease18.95254888215
heart failure incidence increases18.782564580814
jacc heart fail18.673112610951
treatment of preserved cardiac function heart failure18.550149920084
palliative care18.44179994736
total cost of heart failure18.265902668449
nyha functional class iii heart failure patients18.217454040627
medical therapy17.964918147966
natural progression of heart failure17.882072954752
emergency diagnosis of heart failure17.620725961188
framingham heart study17.498080233577
other risk factors17.278687223499
heart murmur17.23910699358
heart pumps17.23910699358
randomized aldactone evaluation study17.087538022693
clinical manifestations16.83639757978
american college of cardiology/american heart association task force16.535658500992
sinus rhythm16.413388798409
rate control16.264836064977
isosorbide dinitrate15.731731418229
atrial fibrillation14.831171004269
effect of enalapril14.810436756732
reduced left ventricular ejection fractions14.67049846495
clinical practice guidelines14.331909251528
standard oral heart failure medications14.300957322253
ventricular systolic dysfunction14.250752107168
cardiac resynchronization-heart failure14.182398182435
b-type natriuretic peptide14.104527674707
seattle heart failure model14.084936415565
heart outcomes prevention evaluation study investigators13.643378821151
natriuretic peptide13.63463239761
myocardial dysfunction13.339979404194
large randomized controlled trial13.319992037631
significant difference13.239003678587
cardiac resynchronization13.127272139645
randomized trial12.804343491775
mcmurray jj12.728649475109
symptomatic patients12.688455161287
primary prevention12.638597791832
weight gain12.358602863443
pulmonary artery12.189889456761
high-risk patients12.160801393263
natriuretic peptide-guided therapy12.148130455988
presence of risk factors12.135032696779
mechanical circulatory support12.05693358307
nonischemic cardiomyopathy11.988264044641
svensson am11.741784511603
ventricular function11.641674912519
left ventricular ejection fraction11.525563868743
asymptomatic patients11.500975876433
functional capacity11.465313506452
nhlbi heart failure clinical research network11.358108274759
survival study11.233623397695
icd implantation11.19016562612
jessup m. stage b heart failure11.118430014839
eplerenone post-acute myocardial infarction heart failure efficacy10.997210408437
hospitalization rates10.954451150103
global myocardial ischemia10.912809166167
systolic blood pressure10.88520498932
ventricular volume10.702456190343
quality of life10.669676460234
physical examination10.602356529148
microvascular disease10.487221590056
right heart catheterization10.4799301148
specific causes10.392304845413
bozkurt b10.392304845413
trial investigators10.388739120117
reduced risk10.261558002989
controlled trial10.182919580087
nyha functional classification10.142555229712
clinical practice10.102415878263
pulmonary disease10.019940278469
cardiovascular mortality9.9312951847935
inotropic agents9.7291971163912
clinical outcomes9.6522804347375
moderate symptoms9.6411410273358
systolic blood pressure intervention trial9.6084651563334
aldosterone antagonist9.603257618831
study investigators9.5876942772625
current guidelines9.5803106027242
intravenous inotropic agents9.5374267604657
acute coronary syndrome9.4985091341904
american college of cardiology foundation9.3845904936053
controlled trial of patients9.1337089660923
american heart association statistics committee8.9787339517073
coronary revascularization8.9720926873273
cohn jn8.9442719099992
other causes8.9442719099992
induced coronary artery disease8.847853494422
specific cause8.8186670410496
disease control8.8186670410496
circ heart fail8.7264615096001
angiotensin receptor?neprilysin inhibitor8.7211839342619
survival study investigators8.6332728113428
wilson j8.6289073396314
young j8.6289073396314
lindenfeld j8.6289073396314
consensus trial study group8.5920924788324
symptomatic nyha class ii8.5915760184806
ace inhibitor therapy8.5800543746011
systemic disease8.5291344178582
effect of carvedilol8.5242951907087
krishnaswamy p8.4852813742386
cardiovascular disease hospitalization8.4455351182242
low cardiac output8.4200214932682
third heart sound8.4078800764062
initial laboratory evaluation8.3925789638182
evaluation of patients8.3725700160278
casey de jr8.2985253256109
randomised trial8.1812469784701
cardiac-resynchronization therapy8.1739324901763
usual care8.1221727394757
adverse changes8.1072009288422
reduced mortality8.0770059874436
ischemic cardiomyopathy7.9921760297609
angiotensin-converting enzyme7.9774438454175
lee kl7.8964440777149
champion trial study group7.8789835426777
6-minute walk test7.845962916071
haarbo j7.7970979610547
neaton j7.7970979610547
pogue j7.7970979610547
emberson j7.7970979610547
bosch j7.7970979610547
mccord j7.7970979610547
gong j7.7970979610547
gallagher j7.7970979610547
mathew j7.7970979610547
care of patients7.7844093950776
randomized aldactone evaluation study investigators7.7057858141598
poor functional status7.5438910962342
angiotensin receptor?neprilysin inhibitors7.5417066766768
right ventricular function7.5395190889965
clinical guidelines7.5352689577953
implantable pulmonary artery pressure7.5053420380578
cardiomems heart sensor7.490569582348
left ventricular hypertrophy7.4659422745248
cardiac resynchronization therapy7.461797978668
acute pulmonary disease7.4527789849152
glycemic control7.4448388728168
randomized trial danish7.377854493525
american college of cardiology foundation/american heart association task force7.3615515350663
other risk factor7.3557314102613
20,985 patients7.3484692283495
swedberg k7.3484692283495
blood volume7.3256830029694
first hospitalization7.3256830029694
primary risk factors7.2867046089153
inhibitor ivabradine trial7.2716336769238
renal disease7.2560172494525
functional class guides treatment7.2225756445557
quality of care7.2217462736946
observational study7.1407419177511
zannad f7.1352426900163
subset of patients7.1352426900163
cardiovascular events7.1131176401557
medical history7.0851677179898
clinical studies7.0568830507494
disease progression6.9009799013736
advanced disease6.9009799013736
volume overload6.8795812565008
natriuretic peptide levels6.7807496594118
loop diuretics6.700737917669
clinical status6.673987930963
effects of treatment6.6706214794855
ventricular size6.6604914252356
danish study6.6452091262532
implantable cardioverter-defibrillator6.6400915182019
angiotensin-receptor blockers6.6400915182019
kazanegra r6.6195018392937
prophylactic implantation6.6195018392937
boineau r6.6195018392937
latini r6.6195018392937
outcomes of patients6.5934915059146
range of risk factor levels6.558071028175
american college of cardiology6.5412422314049
effects of candesartan6.4474195909412
usual clinical care6.3802363071573
major risk factors6.3655227986524
miracle icd trial6.3547610473256
history of hospitalization6.3442275806434
adverse effects6.3442275806434
cannom ds6.3442275806434
cardiac insufficiency bisoprolol study ii6.3179627563086
multicenter insync icd randomized clinical evaluation6.3095633402878
relative risk6.3086842910598
lifetime risk6.3086842910598
risk score6.3086842910598
atherosclerosis risk6.3086842910598
influence risk6.3086842910598
accf/aha guideline6.2926925672916
functional capacity of patients6.2273448933373
left-ventricular ejection fraction6.2133136519014
accf/aha guidelines6.1771812387753
subjective symptoms6.160140576482
serum digoxin levels6.1273116840957
klein h6.1256286272176
renal insufficiency6.1256286272176
effect of digoxin6.1015588940837
modification of risk factors6.0675163483893
other patients6.0615465140299
ventricular dyssynchrony6.0184333968691
ventricular arrhythmias6.0184333968691
ventricular enlargement6.0184333968691
stevenson lw6
shortness of breath6
such cardiovascular risk factors5.9621371715169
valvular disease5.957892135529
solvd investigators5.9436557324017
val-heft investigators5.9436557324017
charm investigators5.9436557324017
term gheart failure h5.9368741417647
clinical syndrome5.9341076602399
dietary sodium restriction5.9191344907092
controlled clinical trials5.8878964084292
cardiogenic shock5.8856619127654
other mechanisms5.8856619127654
previous myocardial infarction5.8653533983426
other adverse effects5.8601559088987
elevated systemic blood pressure5.8538734383683
significant differences5.8259012604879
oral diuretic therapy5.8249031191339
monitoring of pressure5.8106700157786
myocardial remodeling5.7991674783197
myocardial structure5.7991674783197
cardiovascular outcomes5.7850152170382
j card fail5.7714994741381
exercise capacity5.7326567532262
symptomatic management5.7326567532262
champion trial investigators5.717797486992
harrison a5.7005397655436
krum h5.7005397655436
rawshani a5.7005397655436
recognized risk factors5.6710361016125
nonmodifiable risk factors5.6710361016125
intensive blood pressure5.6586941766333
low doses5.5663153674275
packer m5.5663153674275
rates of hyperkalemia5.5663153674275
jessup m5.5663153674275
important adverse effects5.547933582892
daily pulmonary artery pressure readings5.5321413028549
cardiac toxicity5.5193380421438
cardiac output5.5193380421438
nonfatal myocardial infarction5.4820834359262
rates of hospitalization5.4772255750517
charm-preserved trial5.4711295994695
charm-alternative trial5.4711295994695
cardiac pump function5.442323265122
non-ischemic cardiomyopathy treatment evaluation5.438910834863
symptoms of volume overload5.4146047111091
advanced therapy5.3787500669746
large population study5.3481384667782
masson s5.3446902355676
barlera s5.3446902355676
madit-crt trial investigators5.3441695264733
prospective randomized cumulative survival study group5.3249941204811
gerdes am5.3049500053196
kucharska-newton am5.3049500053196
significant effect5.3049500053196
emphasis-hf study group5.2974318574102
held p5.26429605181
jourdain p5.26429605181
magnetic resonance imaging5.2414827884178
myocardial sarcomere5.2401393526787
clinical characteristics5.2226777991727
clinical benefit5.2226777991727
clinical assessment5.2226777991727
ventricular noncompaction cardiomyopathy results5.200849059796
optimal medical therapy5.1893987221281
mild symptoms5.1800401282227
functional status5.1800401282227
blood tests5.1800401282227
weight monitoring5.1800401282227
hypomagnesemia increase risk5.1660198496359
sudden death5.1510191538028
cardiac muscle5.1363228010461
cardiac structure5.1363228010461
digoxin dose5.0914597900437
ventricular dysfunction delays onset5.0761464007087
left-ventricular systolic function5.0719730249202
multinational study investigators5.0657970191009
multicenter automatic defibrillator implantation trial ii investigators5.0514818398486
elderly study5.0492670327448
effects of enalapril5.0453784915223
maladaptive ventricular hypertrophy5.0063266198115
enalapril group4.9737947036147
high risk of re-admission4.9241689779833
patient's clinical status4.9027522910779
randomised trial of losartan4.8760319739572
quality measures4.8645985581956
fluid restriction4.8645985581956
therapy changes4.8602493374348
drug therapy4.8602493374348
randomised placebo-controlled study4.8490562872798
increase exercise capacity4.8465663976689
ace inhibitor ramipril4.8409406455445
practice guidelines4.8339055525626
diabetes care4.8294728055328
independent risk factor4.8284476525076
absence of symptoms4.8205705136679
loop diuretic4.8205705136679
refractory symptoms4.8205705136679
pressure overload4.8026164940938
other factors4.7867398586908
sprint research study group4.7637250806784
disease process4.7381372205376
reduced diastolic4.7381372205376
lung disease4.7381372205376
clinical suggestions4.7192221235411
clinical suspicion4.7192221235411
african american patients4.7170518987602
large double-blind trial4.6980201586465
tognoni g4.6806946386414
ischemic stroke4.6806946386414
pulmonary causes of exercise limitation4.6806946386414
sudden cardiac death4.6575419678526
cardiac sarcoidosis4.6411915742122
cardiac involvement4.6411915742122
cardiac workload4.6411915742122
cardiac valves4.6411915742122
cardiac amyloidosis4.6411915742122
cause of death4.6361821858297
stars-bnp multicenter study4.6220442888931
mild patients hospitalization4.6196709652247
chronic atrial fibrillation4.6132323629156
association of serum digoxin concentration4.5916055846449
patient's nyha4.5825756949558
k?ber l4.5590141139096
effects of valsartan4.5590141139096
combination of ace inhibitors4.5582562960338
coronary angiography4.4860463436637
metoprolol cr/xl randomised intervention trial4.4287921839498
diabetes mellitus4.4267276788013
inefficient ventricular contractile function4.4248034309981
family history of cardiomyopathy4.4088173933227
initial evaluation4.3679267425564
prospective clinical trials4.3678557314809
bnp levels4.3558771746929
severity of symptoms4.3558771746929
oral diuretic dose4.3440506352097
other measures4.3253077270721
american college of physicians4.3231140296575
left-ventricular dysfunction4.2813902858562
conduction abnormalities4.2813902858562
givertz mm4.2813902858562
maladaptive ventricular remodeling4.2513258303959
prophylactic icd implantation4.2484406376281
other important guidelines4.2448203141176
right ventricular free wall4.2425598510497
composite outcome4.2294850537623
daubert jp4.2294850537623
plasma digoxin levels4.2227675591121
peripartum cardiomyopathy4.1824461364775
other systemic disorders4.1689486953466
cooperative north scandinavian enalapril survival study4.1683924274728
oral furosemide therapy4.1633714773242
recent observational study4.1623049031538
prophylactic icd4.1408245796559
objective measures of disease status4.1301657152851
sinus rate4.1195342878142
oxygen-rich blood4.1195342878142
blood flow4.1195342878142
blood counts4.1195342878142
reduced rates4.090623489235
à-blocker therapy4.0869662450882
first-line therapy4.0869662450882
appropriate therapy4.0869662450882
evaluation of losartan4.0648138508249
other important disorders4.0632051688874
routine care4.0610863697379
specific clinical indication4.0577694145156
exercise training4.0536004644211
role of palliative care4.0300296715324
maisel as4
gbridge therapy h3.9993486932656
pressure-guided management of patients3.9654064565002
serum levels of electrolytes3.9468319327726
moss aj3.9359793425309
staging system3.9359793425309
ezekowitz ja3.9359793425309
defibrillator implantation3.9359793425309
fluid retention3.9359793425309
patient information3.9359793425309
controlled studies3.9359793425309
gventricular dysfunction h3.9320768183025
effect of diuretics3.8985489805273
left bundle branch block3.8735854825302
adverse events3.8729833462074
pulmonary capillary wedge pressure3.8536671042695
arni treatment3.8512851068431
goal of treatment3.8512851068431
early treatment3.8512851068431
potential adverse effects3.8467222990467
intolerable adverse effects3.8467222990467
continuous intravenous inotropic agents3.8375885893579
carvedilol post-infarct survival control3.8375885893579
lo studio della streptochinasi nell finfarto miocardico-heart failure trial3.8349221943338
laboratory evidence3.8067540958393
peripheral vascular disease3.8027429028336
houston-miller n3.7976578442319
kagiyama n3.7976578442319
freemantle n3.7976578442319
heterogeneous study populations3.7817049765835
ivabradine group3.7792667089114
basic palliative care3.7666884513457
palliative care addresses3.7666884513457
aha stage c3.7578442412245
specific type of cardiomyopathy3.7439265731403
other treatment decisions3.7430197238696
patient's daily weight3.7288210710016
hall wj3.7224194364084
qrs duration3.7224194364084
bauman jg3.7224194364084
muscular dystrophy3.7224194364084
abraham wt3.7224194364084
larson mg3.7224194364084
pfeffer ma3.7224194364084
incessant tachycardia3.7224194364084
yancy cw3.7224194364084
bourge rc3.7224194364084
intravenous loop diuretics3.719046769829
global mortality3.7126875376323
adequate doses of ace inhibitors3.7098517435797
population-based reykjavik study3.708192102729
only therapy3.6929908877475
ordinary physical activity3.6830484346607
invasive evaluation3.6729739399065
safety of exercise training3.6666352749723
advanced stages3.6628415014847
b-type natriuretic peptide assay3.6628415014847
supervised exercise3.6628415014847
a1c levels3.6628415014847
other noninvasive imaging3.6590516533172
effect of metoprolol cr/xl3.6529276674218
european society of cardiology3.6467519140054
direct myocardial toxin?it3.6231148419824
increased mortality3.6161715709604
regional dysfunction3.6002057436785
sodium restriction3.6002057436785
digoxin toxicity3.6002057436785
serum level3.6002057436785
controlled trials3.6002057436785
inhibitor ramipril3.5840246342157
angiotensin-converting-enzyme inhibitor3.5840246342157
variety of patients3.5676213450082
arrhythmogenic right ventricular dysplasia3.567553370247
elevated total cholesterol levels3.5620857880302
health care costs3.561271038656
cardiovascular system3.5565588200778
volume status3.5565588200778
clinical slide set3.5447880909253
ability of icd implantation3.5376050502214
danish investigators3.5341188430494
renal excretion of digoxin3.503082197055
other medications3.4996355115806
other à-blockers3.4996355115806
other lifestyle changes3.4877505632064
miracle icd3.4820045452271
appropriate serum level of digoxin3.473041544387
hemodynamically significant ventricular septal defects3.4683547086532
felker gm3.4641016151377
cigarette smoking3.4641016151377
benjamin ej3.4641016151377
granger cb3.4641016151377
brown mw3.4641016151377
family history3.4641016151377
end-organ hypoperfusion3.4641016151377
davis ce3.4641016151377
few days3.4641016151377
stable weight3.4641016151377
united states3.4641016151377
hiv infection3.4641016151377
d fagostino r jr3.4519247197843
first-line drug therapy3.4458199066465
nondiabetic control group3.4312578792284
other relevant pqrs quality measures3.4278736200193
spironolactone group3.4149529703483
collaborative care3.4149529703483
guided care3.4149529703483
decrease hospitalization3.4086580994025
bundle branch block3.3967626591299
effect of spironolactone3.3895612242702
trabeculated myocardial architecture3.3863633634254
aha stage3.3635856610149
use of bnp3.3635856610149
prophylactic defibrillator implantation3.3604214537127
other performance measures3.3446807651574
other tests3.3437015248821
meta-analysis global group3.3285607270274
cardiopulmonary exercise test3.3244690547396
smith r3.3097509196469
natriuretic peptides3.3097509196469
genetic disorders3.3097509196469
careful monitoring of serum potassium levels3.2957569692557
severe cardiogenic shock3.2598444275496
current measures3.2531531233956
time-to-furosemide treatment3.2385318404644
hospital admission rate3.2377408137211
angiotensin-converting enzyme inhibitors3.2368032890054
atrial arrhythmia3.2237097954706
hospitalized patients3.2237097954706
selected patients3.2237097954706
natural history3.2237097954706
elevated levels of low-density lipoprotein cholesterol3.2113286293254
low high-density lipoprotein cholesterol levels3.2113286293254
detrimental effect of sodium restriction3.2033666669598
functional mitral regurgitation3.2031009475288
cardiopulmonary exercise testing3.2031009475288
obesity-related cardiomyopathy3.1779718278113
dilated cardiomyopathy3.1779718278113
tachycardia-induced cardiomyopathy3.1779718278113
diabetic cardiomyopathy3.1779718278113
eplerenone group3.1779718278113
hypertrophic cardiomyopathy3.1779718278113
ordinary physical activity results3.1616447614742
prediction of survival3.1463462836458
expected survival3.1463462836458
survival advantage3.1463462836458
meaningful survival3.1463462836458
noninvasive imaging3.1301691601466
long-term use3.1301691601466
aborted cardiac arrest3.1231391134797
smith al3.1054227990715
structured cardiac rehabilitation program3.0918884056739
high doses3.080070288241
large multicenter3.080070288241
nt-probnp levels3.080070288241
thiazide diuretic3.080070288241
electrolyte levels3.080070288241
current aha guidelines3.0668124740328
yancy c3.0628143136088
other genetic disorders of iron metabolism3.0600833060707
different types of care3.0569032462135
elevated jugular venous pressure3.0400841363597
systemic disorder3.0274001040351
practice improvement3.0274001040351
systemic diseases3.0274001040351
iron overload3.0274001040351
daily weight checks3.0261714988458
iervasi g. thyroid replacement therapy3.0061164174793
natriuretic peptide-based screening2.9937951655239
observational studies2.9906975624424
doukky r2.9906975624424
segal r2.9906975624424
quigg r2.9906975624424
comenzo r2.9906975624424
quality indicators2.9906975624424
marchioli r2.9906975624424
davies r2.9906975624424
lieberman r2.9906975624424
cody r2.9906975624424
deo r2.9906975624424
cremo r2.9906975624424
amirnovin r2.9906975624424
physical activities2.9718278662008
physical exam2.9718278662008
physical therapists2.9718278662008
predictors of mortality2.9525917237372
laboratory tests2.9428309563827
such reversible cardiac conditions2.9390867394432
hospital readmission rates2.9355985352441
long-term inotropic infusion2.9279034960725
specific structural abnormalities2.9279034960725
physician quality reporting system2.9278526754426
riegel b2.9129506302439
history of angioedema2.9129506302439
end-of-life management2.9129506302439
olofsson b2.9129506302439
increased bnp2.9129506302439
levin b2.9129506302439
eliasson b2.9129506302439
symptom management2.9129506302439
roniker b2.9129506302439
significant data2.9129506302439
wilkoff b2.9129506302439
claggett b2.9129506302439
diastolic relaxation2.9129506302439
reduced hospitalizations2.8925076085191
unexplained weight gain2.8844991406148
angiotensin-receptor blocker valsartan2.8844991406148
intensive hypertension control2.8844991406148
lot of weight gain2.8844991406148
angiotensin-converting-enzyme inhibitors2.882121417102
acute exacerbations2.8716217110259
placebo group2.8716217110259
sacubitril?valsartan group2.8716217110259
epicardial coronary arteries2.8536385282275
thyroid-stimulating hormone levels2.8536385282275
maggioni a2.8502698827718
left ventricle2.8502698827718
outpatient dose2.8284271247462
routine use2.8284271247462
ordinary activity2.8284271247462
selective aldosterone blocker2.8210130123402
combination of isosorbide dinitrate2.8077989890847
taylor al2.8060662632967
symptomatic bradycardia2.7831576837137
diuretic effectiveness2.7831576837137
lee ds2.7831576837137
diuretic strategies2.7831576837137
diuretic adjustments2.7831576837137
à-blockers carvedilol2.7831576837137
biomarker intensified treatment2.7578805125536
overall mortality2.7476962050545
structured aerobic exercise program2.746743631666
liver function2.7355647997348
rosengren a. glycaemic control2.7285232036427
levy d2.7108060108295
atrial abnormality2.7108060108295
important characteristics2.7108060108295
important organs2.7108060108295
long-term safety2.7108060108295
wide range of causes2.6960123091946
nonvalvular atrial fibrillation2.6889452937027
shift investigators2.6853496142827
topcat investigators2.6853496142827
paradigm-hf investigators2.6853496142827
warcef investigators2.6853496142827
gissi-hf investigators2.6853496142827
hf-action investigators2.6853496142827
hope investigators2.6853496142827
acute dyspnea2.6723451177838
formal exercise programs2.66716827534
other shunts2.6591479484725
le helloco a2.6571971456127
elkayam u. peripartum cardiomyopathy2.6521704180372
v-heft va cooperative studies group2.6379831394264
tolerated dose2.632148025905
significant reductions2.632148025905
last dose2.632148025905
sodium intake2.632148025905
significant reduction2.632148025905
angiotensin-receptor blocker2.632148025905
elevated bnp2.632148025905
current medications2.632148025905
ann intern med2.6207413942089
selective aldosterone antagonist2.6084654714896
several consensus guidelines2.6043085235871
heterogeneous group of outpatients2.5958936998277
hemodynamic monitoring2.5900200641113
cushman m2.5900200641113
baggett c2.5755095769014
avezum a2.5755095769014
perez a2.5755095769014
rapezzi c2.5755095769014
chavelas c2.5755095769014
kiran a2.5755095769014
dan a2.5755095769014
barth c2.5755095769014
dyer a2.5755095769014
yilmaz a2.5755095769014
shi h2.5755095769014
castaigne a2.5755095769014
mangla a2.5755095769014
henrick a2.5755095769014
dubost-brama a2.5755095769014
laupacis a2.5755095769014
kopp a2.5755095769014
ukena c2.5755095769014
avogaro a2.5755095769014
conlon c2.5755095769014
kadish a2.5755095769014
glomerular filtration rate2.5697965868507
tolerated dose of à-blockers2.5697965868507
intravenous bolus2.5457298950218
definitive evidence2.5457298950218
strong evidence2.5457298950218
aldosterone antagonists2.5457298950218
causative factors2.5457298950218
digitalis investigation group2.5454319088428
short-term symptomatic benefits2.5423029068338
used loop diuretics2.5132368765511
parasuraman s. glycemic control2.5020668097181
in-hospital mortality2.4828237961984
physician quality reporting initiative?that clinicians2.4754341287137
overt cardiogenic shock2.4662120743305
rapid b-natriuretic peptide assay2.4494897427832
advanced therapies2.4494897427832
primary outcome2.4494897427832
kavalieratos d2.4494897427832
logeart d2.4494897427832
same population2.4494897427832
lifestyle modifications2.4494897427832
aguilar d2.4494897427832
johnstone d2.4494897427832
ettehad d2.4494897427832
mozaffarian d2.4494897427832
gras d2.4494897427832
valvular abnormalities2.4322992790978
joshua-gotlib s2.4147364027664
franz?n s2.4147364027664
kuroda s2.4147364027664
homma s2.4147364027664
ziesche s2.4147364027664
gudbj?rnsdottir s2.4147364027664
non?left bundle branch block pattern2.3924623977026
carson p2.3784142300054
clopton p2.3784142300054
severe comorbidities2.3784142300054
maximum dose2.3784142300054
beyne p2.3784142300054
severe signs2.3784142300054
sleight p2.3784142300054
gueffet p2.3784142300054
use age2.3784142300054
elliott p2.3784142300054
mohacsi p2.3784142300054
afterload-reducing agents2.3784142300054
duc p2.3784142300054
dennison himmelfarb c2.3672935308725
terms gcardiomyopathy h2.3672935308725
dei cas a2.3672935308725
systemic lupus erythematosus2.3490100793233
continuous intravenous administration2.3490100793233
multicenter guide-it2.3403473193207
komajda m2.3403473193207
lenski m2.3403473193207
miftaraj m2.3403473193207
diagnostic tests2.3403473193207
lind m2.3403473193207
b?hm m2.3403473193207
fiuzat m2.3403473193207
olsson m2.3403473193207
à-blocker carvedilol2.3403473193207
ledwidge m2.3403473193207
semigran m2.3403473193207
electrocardiographic monitoring2.3403473193207
hospital-level 30-day mortality2.3101522238684
robust predictor of mortality2.3101522238684
oral anticoagulants2.3003266337912
nma/pcna guideline2.3003266337912
oral torsemide2.3003266337912
patient's outpatient2.3003266337912
guiding evidence2.3003266337912
conflicting evidence2.3003266337912
optimal therapeutic range2.2894284851067
replacement device2.2795070569548
maisel a. utility2.2449240966188
hood wb jr2.2390395117024
several medications2.2133638394006
subjective assessment2.2133638394006
modification of hypertension2.2133638394006
martinez f2.2133638394006
healthcare research2.2133638394006
2-lb increase2.2133638394006
avery e2.2133638394006
5-lb increase2.2133638394006
diverse range2.2133638394006
impact of diabetes2.2133638394006
general population2.2133638394006
patient's subjective experience2.1955146386099
stroke statistics subcommittee2.1822472719434
role of lifestyle modifications2.1822472719434
deswal a. relationship of hemoglobin2.1810154653305
nonsudden death2.165736770668
hemodynamic overload2.1406951429281
thiazide diuretics2.1406951429281
tobacco use screening2.1398263878673
many genetic cardiomyopathies2.1398263878673
alternative imaging methods2.1398263878673
ojamaa k. thyroid hormone2.1351847961967
serious health condition2.1169328630255
thorgeirsson g2.1147425268811
thabut g2.1147425268811
meurers g2.1147425268811
johnson g2.1147425268811
dagenais g2.1147425268811
jondeau g2.1147425268811
ginn g2.1147425268811
noninvasive computed tomographic angiography2.1039790110173
author thanks lee r. goldberg2.0827594879848
effective gsliding h regimen2.0812192439376
djousse l2.0597671439071
hood wb2.0597671439071
tavazzi l2.0597671439071
long-term benefit2.0597671439071
damman k2.0597671439071
rapid measurement2.0597671439071
matsushita k2.0597671439071
primary prophylaxis2.0597671439071
lenert l2.0597671439071
ramasubbu k2.0597671439071
malmberg k2.0597671439071
additional medications2.0597671439071
kappenberger l2.0597671439071
angelici l2.0597671439071
ferdinand k2.0597671439071
fibrofatty replacement2.0597671439071
videb?k l2.0597671439071
2-dimensional doppler echocardiography2.0396489026555
two-dimensional doppler echocardiography2.0396489026555
additional diagnostic testing2.0396489026555
prognostic value of changes2.0396489026555
raimondi e2
korup e2
chemotherapeutic agents trastuzumab2
total distance2
tallon e2
funck f2
suspected cases2
long-standing untreated hypertension2
daubert jc2
mahfoud f2
million persons2
7.5 mg2
beauvais f2
donal e2
million hospital discharges2
hemoglobin a1c2
erdmann e2
o fconnell e2
prospective comparison of arni2
home health staff1.9786024464679
lindenfeld ja1.9679896712654
prognostic information1.9679896712654
high-risk populations1.9679896712654
combination of hydralazine1.9679896712654
downloadable guideline algorithm1.9559811771959
wall-motion abnormalities1.9343364202677
thune jj1.9343364202677
active ischemia1.9343364202677
mamdani mm1.9343364202677
redfield mm1.9343364202677
patient's circumstances1.9343364202677
teerlink jr1.9343364202677
scheinman mm1.9343364202677
glucose abnormalities1.9343364202677
colvin mm1.9343364202677
excess iron deposition1.9063685859939
long-acting metoprolol succinate1.9063685859939
implantable cardioversion defibrillation1.9063685859939
sustained efficacy1.8612097182042
goldberg lr1.8612097182042
alcohol consumption1.8612097182042
vago t1.8612097182042
efficacy of icds1.8612097182042
many areas1.8612097182042
absence of arrhythmia1.8612097182042
remme wj1.8612097182042
continuous infusion1.8612097182042
social support1.8612097182042
direct toxicity1.8612097182042
new agent1.8612097182042
first calls1.8612097182042
hardarson t1.8612097182042
routine anticoagulation1.8612097182042
definitive therapies1.8612097182042
major hemorrhage1.8612097182042
aspelund t1.8612097182042
yamaguchi t1.8612097182042
objective predictors1.8612097182042
callender t1.8612097182042
common precursor molecule1.8493111942973
composite end point1.8493111942973
regular measurement of electrolytes1.8171205928321
improved safety profiles1.8171205928321
van veldhuisen dj1.7817974362807
early postpartum period1.7817974362807
complete follow-up results1.7817974362807
several regulatory agencies1.7817974362807
review of animal models1.7817974362807
composite of time1.7782794100389
common questions1.7782794100389
preventable syndrome1.7782794100389
frequent hospitalizations1.7782794100389
combination of sacubitril1.7782794100389
heart-failure events1.7782794100389
recurrent hospitalizations1.7782794100389
neyra ja1.7782794100389
curtis jp1.7782794100389
biventricular pacing1.7782794100389
boehmer jp1.7782794100389
coats aj1.7782794100389
cowley aj1.7782794100389
peripheral edema1.7320508075689
same benefits1.7320508075689
strong muscle1.7320508075689
collins kj1.7320508075689
cushman wc1.7320508075689
aortic regurgitation1.7320508075689
maggioni ap1.7320508075689
levy wc1.7320508075689
remme w1.7320508075689
wang y1.7320508075689
stable outpatients1.7320508075689
peak oxygen consumption1.6983813295649
paroxysmal nocturnal dyspnea1.6983813295649
last trimester of pregnancy1.6983813295649
giant cell myocarditis1.6983813295649
shantsila e. anticoagulation1.6983813295649
katus ha1.6817928305074
franzosi mg1.6817928305074
whellan dj1.6817928305074
evans jc1.6817928305074
sound waves1.6817928305074
freudenberger rs1.6817928305074
one meta-analysis1.6817928305074
stress testing1.6817928305074
increases regression1.6817928305074
wilber dj1.6817928305074
muscular dystrophies1.6817928305074
white persons1.6817928305074
episodic arrhythmia1.6817928305074
ellis sj1.6817928305074
desai as1.6817928305074
packer dl1.6817928305074
qrs prolongation1.6817928305074
nielsen jc1.6817928305074
tycon le1.6817928305074
systematic review1.6817928305074
rare disorder1.6817928305074
klein hu1.6817928305074
major problem1.6817928305074
beanlands rs1.6817928305074
unpredictable exacerbations1.6817928305074
elimination of tachycardia1.6817928305074
slight limitation1.6817928305074
poor prognosis1.6817928305074
many parts1.6817928305074
black persons1.6817928305074
rheumatologic diseases1.6817928305074
ha ac1.6817928305074
cleland jg1.6817928305074
marked limitation1.6817928305074
wall thickness1.6817928305074
serial echocardiography1.6817928305074
enrollment goal1.6817928305074
drink alcohol1.6817928305074
heritable disorder1.6817928305074
vasan rs1.6817928305074
african americans1.6817928305074
ambrosius wt1.6817928305074
cochrane database syst rev1.6817928305074
wood ma1.6817928305074
dietary recommendations1.6817928305074
million people1.6817928305074
keteyian sj1.6817928305074
select therapies1.6817928305074
ellison rc1.6817928305074
inflammatory diseases1.6817928305074
suitable alternative1.6817928305074
pocock sj1.6817928305074
insoluble fibrillar proteins1.5874010519682
myocyte adipose accumulation1.5874010519682
autosomal dominant mutations1.5874010519682
complex psychosocial issues1.5874010519682
emdin ca1.5650845800733
fitzpatrick ap1.5650845800733
low-sodium diet1.5650845800733
n-terminal pro?b1.5650845800733
lower-extremity edema1.5650845800733
n-terminal pro-brain1.5650845800733
das sr1.5650845800733
rathore ss1.5650845800733
bristow mr1.5650845800733
anstrom kj1.5650845800733
former condition1.5650845800733
avery cl1.5650845800733
collins sp1.5650845800733
decrease afterload1.5650845800733
jensen dn1.5650845800733
audrey wu1.5650845800733
hollander je1.5650845800733
costanzo mr1.5650845800733
nery pb1.5650845800733
khan ss1.5650845800733
gudnason v1.5650845800733
ariti ca1.5650845800733
dr. wu1.5650845800733
shinbane js1.5650845800733
loehr lr1.5650845800733
wang tj1.5650845800733
second calls1.5650845800733
professional roles1.5650845800733
nowak rm1.5650845800733
matsue y1.5650845800733
emergency department1.5650845800733
developed areas1.5650845800733
anderson kp1.5650845800733
rizkala ar1.5650845800733
juurlink dn1.5650845800733
ann arbor1.5650845800733
nonpharmacologic interventions1.5650845800733
specialized interventions1.5650845800733
cavity size1.5650845800733
leon ar1.5650845800733
short-term basis1.5650845800733
borer js1.5650845800733
carey rm1.5650845800733
previous version1.5650845800733
enough data1.5650845800733
goldsmith sr1.5650845800733
hereditary hemochromatosis1.5650845800733
intracerebral hemorrhage1.5650845800733
overall frailty1.5650845800733
variety of antigens1.5650845800733
intracardiac device1.5650845800733
impact of obesity1.5650845800733
wilson pw1.5650845800733
nutritional supplements1.5650845800733
hypersensitivity myocarditis1.5650845800733
poole je1.5650845800733
hereditary anemias1.5650845800733
bekelman db1.5650845800733
aortic stenosis1.5650845800733
zareba w1.5650845800733
ibrahim z1.5650845800733
young jb1.5650845800733
mark db1.5650845800733
compared hydralazine1.5650845800733
plasma brain1.5650845800733
low-salt diet1.5650845800733
anderson sg1.5650845800733
various organs1.5650845800733
nutritional deficiencies1.5650845800733
arany z1.5650845800733
martinez fa1.5650845800733
professional organizations1.5650845800733
adamson pb1.5650845800733
kutyifa v1.5650845800733
allergic reaction1.4142135623731
michelson el1.4142135623731
bonow ro1.4142135623731
vision disturbances1.4142135623731
leip ep1.4142135623731
gottlieb so1.4142135623731
cropp ab1.4142135623731
cool extremities1.4142135623731
sinoatrial node1.4142135623731
walsh cr1.4142135623731
painful gynecomastia1.4142135623731
krumholz hm1.4142135623731
arnold jm1.4142135623731
urgent-care setting1.4142135623731
unrealistic expectations1.4142135623731
medicaid services1.4142135623731
fowler mb1.4142135623731
angiotensin-neprilysin inhibition1.4142135623731
mayo clinic1.4142135623731
congenital lesions1.4142135623731
aronow ws1.4142135623731
bates jt1.4142135623731
painless procedure1.4142135623731
past decade1.4142135623731
estes na1.4142135623731
collado fm1.4142135623731
zhang zm1.4142135623731
expert opinion1.4142135623731
chiuve se1.4142135623731
heavy toll1.4142135623731
hazard ratio1.4142135623731
thompson jl1.4142135623731
effort intolerance1.4142135623731
influenza immunization1.4142135623731
thiamine deficiency1.4142135623731
predetermined threshold1.4142135623731
predicted distances1.4142135623731
industrialized countries1.4142135623731
university of michigan1.4142135623731
assmann sf1.4142135623731
ellenbogen ka1.4142135623731
smoke cigarettes1.4142135623731
progressive weakness1.4142135623731
gelfman lp1.4142135623731
linker dt1.4142135623731
bonus payments1.4142135623731
pullicino pm1.4142135623731
bardy gh1.4142135623731
maurer ms1.4142135623731
lefkowitz mp1.4142135623731
endomyocardial biopsy1.4142135623731
gruppo italiano1.4142135623731
noncaseating granulomata1.4142135623731
ikejiani dz1.4142135623731
place chairs1.4142135623731
sex-specific equations1.4142135623731
repeated transfusions1.4142135623731
viable myocardium1.4142135623731
reasonable expectation1.4142135623731
soliman ez1.4142135623731
loeb hs1.4142135623731
daniels lb1.4142135623731
swollen feet1.4142135623731
radionuclide ventriculography1.4142135623731
fconnor cm1.4142135623731
bull da1.4142135623731
euthyroid state1.4142135623731
albert nm1.4142135623731
speed of absorption1.4142135623731
poulin mf1.4142135623731
attractive possibility1.4142135623731
sutradhar sc1.4142135623731
characteristic presentation1.4142135623731
shown promise1.4142135623731
drazner mh1.4142135623731
straight line1.4142135623731
blaha mj1.4142135623731
mentz rj1.4142135623731
cleavage products1.4142135623731
journal circulation1.4142135623731
voors aa1.4142135623731
adams kf1.4142135623731
cooper ls1.4142135623731
extent of disability1.4142135623731
abdominal bloating1.4142135623731
chang pp1.4142135623731
austin pc1.4142135623731
healthy adults1.4142135623731
tool kit1.4142135623731
dao q1.4142135623731
squire ib1.4142135623731
prior chemotherapy1.4142135623731
whelton pk1.4142135623731
nichols ga1.4142135623731
dargie hj1.4142135623731
birnie dh1.4142135623731
future priorities1.4142135623731
morrison lk1.4142135623731
educational material1.4142135623731
self-care guide1.4142135623731
lip gy1.4142135623731
striated muscles1.4142135623731
anorexia nervosa1.4142135623731
executive summary1.4142135623731
obvious explanation1.4142135623731
anker sd1.4142135623731
neurohormonal activation1.4142135623731
j.jacc .2016.03.6051
.0 b013e31829e88071
1.2 ng/ml1
0.8 ng/ml1
2.5 times1

頻出語ITC103

抽出語出現回数 抽出語出現回数 抽出語出現回数
failure236clinician16obesity9
heart217function16activity8
patient145infarction16advanced8
risk53american15adverse8
disease49arb15atrial8
ventricular42blood15current8
mortality41cardiovascular15drug8
-rsb-_NN39hypertension15evaluation8
therapy39severe15higher8
inhibitor35they15hydralazine8
not35à-blocker14important8
you34weight14mild8
symptom33chronic13morbidity8
trial33circulation13more8
ejection30diabetes13placebo8
fraction30digoxin13primary8
myocardial28management13pulmonary8
investigator27significant13addition7
it27survival13all-cause7
other27diuretic12asymptomatic7
who27dose12benefit7
clinical26exercise12change7
coronary26more12congestive7
dysfunction26physical12controlled7
cardiac25which12day7
factor25diastolic11disorder7
hospitalization25functional11enalapril7
artery24history11even7
effect23natriuretic11f7
that23test11greater7
also22condition10however7
systolic22control10hypertrophy7
guideline21diagnosis10information7
less21implantation10j.jacc7
level21large10many7
pressure21peptide10population7
class20renal10prevention7
such20significantly10quality7
what20specific10reduction7
cardiomyopathy19standard10result7
study19symptomatic10sign7
treatment19abnormality9sinus7
I18agent9smoking7
rate18decompensated9status7
death17evidence9support7
outcome17group9systemic7
when17high9volume7
acute16left9ace6
care16lower9blocker6
cause16medical9combination6

複合語候補ITC102

複合語スコア
uncomplicated diverticulitis520.80474927208
acute diverticulitis418.81479435056
complicated diverticulitis248.2289508251
recurrent diverticulitis127.61545808739
complicated disease111.42002809531
acute colonic diverticulitis100.72226537515
uncomplicated disease86.580881619622
abdominal pain76.911661151322
inflammatory bowel disease73.842824849867
increased risk65.214963143546
diverticular disease59.390784046077
incident diverticulitis49.45317468774
abdominal imaging47.23175211037
colonic diverticulitis45.118877898911
history of diverticulitis44.338210423658
symptomatic uncomplicated diverticular disease38.955277706314
strate ll38.359328358189
am j gastroenterol37.152951337623
acute episode35.382742924933
sigmoid diverticulitis35.151543534868
suspected diverticulitis34.725385463817
severe diverticulitis34.275883049016
recurrent disease33.414187838691
american society of colon33.07927853605
dis colon rectum31.175046758317
diagnosis of diverticulitis30.073065967872
elective surgery29.842768221688
abdominal ct28.833736969617
low-fiber diet28.761380723141
clin gastroenterol hepatol28.491801279155
colon cancer28.136031705246
percutaneous drainage26.958995747902
perforated diverticulitis26.044039097863
br j surg26.010395580964
bowel habits25.744787543708
risk of diverticulitis25.427668301235
disease severity23.932331536252
irritable bowel syndrome23.321049637337
antibiotic treatment23.140060868153
immunocompromised patients22.840524575036
high-fiber diet22.304567212867
surgical intervention21.686448086636
acute uncomplicated diverticulitis21.457232736063
initial episode of diverticulitis20.596397618848
clear liquid diet20.045605887726
physical examination19.720768992425
american gastroenterological association19.718763332722
red meat19.027313840044
bowel obstruction18.448253771601
cases of diverticulitis18.172404327683
diverticulitis treatment17.362692731908
mild diverticulitis17.362692731908
acute uncomplicated sigmoid diverticulitis17.346633172924
risk of incident diverticulitis17.338968240675
acute complicated diverticulitis17.156138686604
episode of diverticulitis17.084799980876
acute sigmoid diverticulitis17.056092941653
risk factors16.9443127662
incident episode16.71181620517
recurrent episodes16.486177230327
diverticular bleeding16.431676725155
diverticulitis present16.420620960903
clinical diagnosis16.214401857684
management of diverticulitis16.157806223411
giovannucci el15.874507866387
risk factor15.577291619844
family history of diverticulitis15.175555517272
large abscesses15
colonic resection14.757049888818
low vitamin d levels14.653432934541
mild abdominal pain14.324702914937
elevated leukocyte count14.217014705099
surgical risk14.119453697294
crp levels14.042083915924
elective resection13.953485904069
low fiber intake13.94327126918
other causes13.8654187622
acute abdominal pain13.819656392708
comorbid conditions13.817338054791
studies of diverticulitis13.808041302263
stage ib disease13.70815986105
moderate disease13.63463239761
clinical trial13.558244897081
complicated colonic diverticular disease13.274289840469
recurrent sigmoid diverticulitis13.261380785769
clinical diagnosis of diverticulitis13.035979826083
management of patients13.027111248653
randomized trials12.520676640586
second episode12.485374350864
acute left-sided colonic diverticulitis12.331129506591
intravenous antibiotics12.320281152964
sigmoid colon12.29453329824
magnetic resonance imaging12.237893415933
biliary disease12.12309302806
clinical guidelines12.10960041614
symptoms of diverticulitis11.958114544265
j gastrointest surg11.943790305691
ann surg11.771323825531
inflammatory markers11.618950038622
episodes of diverticulitis11.611132432748
medical treatment11.570030434076
studies of incident diverticulitis11.540915938253
incident disease11.509839833591
ct-proven uncomplicated acute diverticulitis11.437219095645
diverticulitis severity11.425294349672
acute mild-to-moderate colonic diverticulitis11.307695614824
presence of complications10.843224043318
comorbid disease10.779123358892
abdominal rigidity10.669676460234
treatment approach10.63659179389
management of acute complicated10.508684854699
severe signs10.498906534742
prospective diverticulitis diet study10.445350291082
nonsteroidal anti-inflammatory drugs10.414240341373
signs of diverticulitis10.323918866196
ct-proven uncomplicated diverticulitis10.213093392106
differential diagnosis of acute colonic diverticulitis10.186395610963
sigmoid colectomy10.182919580087
outpatient setting10.182919580087
emergency surgery9.9085018560689
primary anastomosis9.7979589711327
acute diverticulitis ranges9.7878329518942
colonic diverticular abscess9.7552358675619
physical activity9.7155955213931
reduced risk of diverticulitis9.7060537262749
oral antibiotics9.603257618831
uncomplicated diverticulitis report9.5457215127482
gastroenterology consultation9.4868329805051
systematic review9.3613892772829
liu yl9.3613892772829
perforated colonic diverticular disease9.2884370061669
first episode9.2115587031938
presumed acute diverticulitis9.1482496032301
prophylactic surgery9.1091108301324
studies of incident disease9.0831785199042
j clin gastroenterol9.0526458194936
chronic abdominal pain9.0239973680098
clear recurrent diverticulitis8.9617026317507
peery af8.9442719099992
first episode of diverticulitis8.9419411546424
pain management8.8011173679339
positive predictive value8.7125736655226
colorectal dis8.7117543493857
randomized trial8.662947082672
uncomplicated hinchey stage ia diverticulitis8.4966700909043
hinchey stages8.4852813742386
exacerbation of pain8.3235829005756
american college of gastroenterology8.2813616669306
elective colectomy8.2390685756285
pelvic examination8.1698094459945
resolution of incident diverticulitis8.1606599210425
severe presentation8.1072009288422
severity of presentation8.1072009288422
severe disease7.9774438454175
computed tomography7.9774438454175
other causes of pain7.8331299233844
other risk factors7.7482600954267
moderate abdominal pain7.7459666924148
colon resection7.7113082540691
location of diverticulitis7.640554827845
predictors of diverticulitis7.640554827845
imaging-confirmed diverticulitis7.640554827845
refractory diverticulitis7.640554827845
colon wall7.5585334178227
unrestricted diet7.5023322452342
incident event7.4737514124485
natural history of diverticulitis7.2325505782833
lifestyle factors7.200411487357
high risk7.1242059320178
increased likelihood of diverticulitis7.0491001548477
abdominal quadrant7.0210419579621
patient information6.9282032302755
development of diverticulitis6.9040206511316
aspects of diverticulitis6.9040206511316
called diverticulitis6.9040206511316
risks of diverticulitis6.9040206511316
diagnosed diverticulitis6.9040206511316
possible diverticulitis6.9040206511316
prevalence of diverticulitis6.9040206511316
probability of diverticulitis6.9040206511316
area of diverticulitis6.9040206511316
am j surg6.87767482356
abdominal lavage6.817316198805
dutch diverticular disease6.7807496594118
chronic abdominal symptoms6.7807496594118
galanko ja6.6400915182019
prospective study6.5934915059146
surgical risk profile6.5571773235281
acute setting6.5189768155556
clinical presentation6.4474195909412
rectal surgeons6.4021717458874
urgent surgery6.3559436556225
diverticular complications6.3442275806434
quality of life6.3442275806434
chan at6.3442275806434
case-by-case basis6.3442275806434
colonic inflammation6.3205987620538
scand j gastroenterol6.276754041649
pelvic inflammatory disease6.269858125439
crp level6.2603383202932
severe pain6.2233297728848
prospective study of patients6.1981751306029
selected patients6.160140576482
immunocompetent patients6.160140576482
ill patients6.160140576482
significant comorbid disease6.147977838025
surgical resection6.1212733961481
elective surgical resection6.0805789927024
oral intake intolerance6.0364780843227
other potential risk factors6.0226744921886
aldoori wh6
andeweg cs6
absence of vomiting6
opiate analgesics6
van goor h5.9875903310478
entire sigmoid colon5.9792452101027
unstable comorbid disease5.8601559088987
urgent surgical management5.8204206926748
laparoscopic approach5.7850152170382
short-term risk5.764242834204
surgical infection society5.7538760949966
iv disease5.7326567532262
liquid intake5.7326567532262
aggressive disease5.7326567532262
surgical approach5.7326567532262
stage ii disease5.7072770564551
complicated recurrence5.6842755776622
american gastroenterological association institute guidelines5.6621318851915
recurrent symptoms5.6596143646095
subsequent episodes5.6568542494924
small abscesses5.6346264945225
west j5.6346264945225
segal j5.6346264945225
mortensen j5.6346264945225
fiber intake5.6346264945225
clinical trial of antibiotics5.6251079610849
healthy lifestyle5.5663153674275
important risk factor5.5567769900768
biliary causes of pain5.4940016093908
laparoscopic lavage5.4711295994695
initial evaluation5.4711295994695
severe clinical presentation5.4400868459948
intestinal diversion5.4216120216591
medical management5.3835632709553
elective sigmoid colectomy5.3778905874053
abdominal radiography5.3348382301168
imaging-confirmed disease5.3348382301168
nonsurgical treatment5.318295896945
role of diet5.3049500053196
urinary causes of pain5.2934292577264
hospital readmission5.26429605181
feinberg r5.26429605181
several studies5.26429605181
bolus r5.26429605181
long-term risk5.2085813742804
decreased risk5.2085813742804
keeley br5.1800401282227
quadrant tenderness5.1800401282227
severe presentations5.1800401282227
red meat intake5.1395931737013
colonic diverticula5.1140388795202
klausner j5.0914597900437
clinical setting5.0914597900437
warusavitarne j5.0914597900437
burcharth j5.0914597900437
winkelhagen j5.0914597900437
groenewoud j5.0914597900437
surgical treatment algorithms5.0846058136676
prospective cohort study5.0712776148561
other sources of pain5.0607888021286
syngal s4.9979987988788
biondo s4.9979987988788
american gastroenterological association institute guideline4.995433437493
int j surg4.9726966324974
prophylactic colonic resection4.9561149113536
int j colorectal dis4.9541639996482
nonsurgical management4.9492320038398
comorbid diseases4.9492320038398
large diverticular abscesses4.9426469173262
potential gynecologic causes of pain4.9353485907905
bowel continuity4.890452073807
common complication of diverticulitis4.8875730663905
american gastroenterological association guideline4.8817587550099
inflamed colon4.8294728055328
abdominal distention4.8205705136679
abdominal ultrasonography4.8205705136679
surgical consultation4.8205705136679
cardiovascular disease4.8205705136679
antimicrobial therapy4.7935634538569
mainstay of therapy4.7935634538569
several other diseases4.7911558306184
complicated cases4.7798869565704
acute cholecystitis4.7660920451877
acute pancreatitis4.7660920451877
acute gastroenteritis4.7660920451877
diffuse peritonitis4.7568284600109
healthy body weight4.75235359513
university of washington school of medicine4.7259408183398
wu k4.6806946386414
intravenous treatment4.6806946386414
laurell h4.6806946386414
predominant risk factors4.6648137477995
population-based study4.6057793515969
monitoring of vitamin d levels4.5823370750615
gynecologic causes4.5799756509618
consumption of nuts4.5590141139096
vu m4.5590141139096
cross-sectional imaging4.5590141139096
nonsteroidal anti-inflammatory drugs increases risk4.5572590051374
kreisler e4.4267276788013
clinical findings4.4267276788013
feculent peritonitis4.4267276788013
clinical evaluation4.4267276788013
cohen e4.4267276788013
generalized peritonitis4.4267276788013
clinical features4.4267276788013
further intervention4.4267276788013
risk factor models4.4104168198003
other conditions4.4093335205248
missed colon cancer4.4088173933227
bowel wall abnormalities4.3594283666312
hospitalization management4.3558771746929
outpatient management4.3558771746929
imaging tests4.3558771746929
chronic symptoms4.3558771746929
biliary imaging4.3558771746929
high red meat intake4.3534525243937
chronic intestinal symptoms4.3177997910652
complicated intra-abdominal infection4.29347189977
leukocyte count4.2813902858562
hjern f4.2813902858562
fuller g4.2813902858562
patient factors4.2813902858562
emergency department4.2813902858562
several guidelines4.2813902858562
appropriate treatment4.2294850537623
recent studies4.2294850537623
am surg4.2128659306105
location of pain4.1617914502878
clinical presentation ranges4.1601676461038
urgent surgical intervention4.1601676461038
misdiagnosed colon cancer4.1207243899042
lam?ris w4.1195342878142
multivariate analysis of risk factors4.116347017223
percutaneous abscess drainage4.0810664157777
red meat consumption4.079297805311
one study4.0536004644211
inflammatory mass4.0536004644211
neumann i. american gastroenterological association institute4.0479034640508
aggressive surgical approach4.0356543087298
multicenter randomized clinical trial4.0154154577774
young age4
high-quality colonoscopy4
serum levels of vitamin d3.9943569808963
population-based cohort study3.9924777441758
urgent sigmoid colectomy3.9895148616825
oral intake3.9842826037303
uncontrolled prospective study3.9468319327726
humes dj3.9359793425309
daniels l3.9359793425309
guide management3.9359793425309
gastrointestinal condition3.9359793425309
wu aw3.9359793425309
multiple recurrent episodes3.923519405471
out-patient management of patients3.9148676411689
hinchey stage iv3.8883225944793
hinchey stage iii3.8883225944793
external validation study3.8467222990467
imaging test3.8336586254776
surgical input3.8336586254776
several observational studies3.8127371719878
other medications3.8067540958393
anti-inflammatory drug3.8067540958393
other forms of colitis3.8027429028336
rosenberg j. treatment of patients3.7969551597047
role of surgery3.7792667089114
elevated crp levels3.7719455481171
lower-abdominal pain3.7606030930864
pain relief3.7606030930864
pain control3.7606030930864
suprapubic pain3.7606030930864
persistent pain3.7606030930864
stomach pain3.7606030930864
special diet3.7511661226171
whole grains3.7224194364084
clinical scenarios3.7224194364084
clinical judgment3.7224194364084
clinical criteria3.7224194364084
golda t3.7224194364084
secondary prevention3.7224194364084
nonaspirin nsaids3.7224194364084
large abscess3.7077927510673
clin infect dis3.7062880231628
chronic intestinal inflammation3.6889272467625
large prospective study of men3.6852485896495
elective open surgery3.6711480767753
such patients3.6628415014847
role of antibiotics3.6628415014847
elective basis3.6628415014847
alternative diagnosis3.6628415014847
differential diagnosis3.6628415014847
anti-inflammatory medications3.6371357625641
missed case of colon cancer3.6182542628146
other features3.6002057436785
family history3.6002057436785
chronic onset of symptoms3.5953592505049
infectious causes3.5840246342157
common causes3.5840246342157
multidetector-row abdominal computed tomography3.5803086727106
gunnarsson u. acute3.5682199372844
alcohol use3.5676213450082
follow-up treatment3.5565588200778
delayed treatment3.5565588200778
appropriate initial imaging method3.5314980576952
small trial3.5227366699756
initial therapy3.5227366699756
third episode3.4996355115806
population-based case-control study3.4877505632064
several classification systems3.4877505632064
multiple comorbid conditions3.4877505632064
c-reactive protein3.4641016151377
hartmann pouch3.4641016151377
martin cf3.4641016151377
cao y3.4641016151377
et al3.4641016151377
bleichrodt rp3.4641016151377
clinical decision rule3.4641016151377
hemodynamic instability3.4641016151377
stages ib3.4641016151377
free perforation3.4641016151377
lidor ao3.4641016151377
yu q3.4641016151377
liver dis3.4641016151377
vrouenraets bc3.4641016151377
united states3.4641016151377
organ transplant3.4641016151377
elective segmental colectomy3.4641016151377
functional bowel disorders3.4600805875852
plain abdominal radiography3.4270399652625
successful nonsurgical treatment3.4199518933534
fiber-rich diet3.3895612242702
diet modification3.3895612242702
other forms of immunosuppression3.3878587775517
other pathologic conditions3.3878587775517
favorable risk profiles3.3727537590827
stage iii3.3635856610149
collaborative study group3.3604214537127
inflammatory colitis present3.3604214537127
natural history3.3503689588345
other reasons3.3503689588345
unstable comorbid conditions3.3244690547396
aga institute clinical guidelines committee3.317096083012
several medications3.3097509196469
severe infection3.3097509196469
nonoperative management3.3097509196469
hinchey stages iii3.3019272488946
imaging method of choice3.3019272488946
genitourinary causes3.2385318404644
clinical scoring system3.2377408137211
increased crp level3.2377408137211
use of aspirin3.2237097954706
aspirin use3.2237097954706
use of nsaids3.2237097954706
intestinal tract3.2237097954706
extent of colon involvement3.2070432430251
dietary recommendations3.2010858729437
high rate of recurrence3.1664800441388
nonsurgical approach3.1622776601684
chronic obstruction3.1622776601684
strate le3.1543421455299
dr. strate3.1543421455299
routine elective resection3.1276103486556
population-based study of twins3.1072325059539
laparoscopic resection3.0885906193877
several decision tools3.0861636884341
feingold d3.080070288241
elderly patients3.080070288241
uncertain diagnosis3.080070288241
colorectal cancer3.080070288241
hinchey classification scheme help3.080070288241
black d3.080070288241
dose of antibiotics3.080070288241
individual patients3.080070288241
inflammatory response3.080070288241
prior diagnosis3.080070288241
stable patients3.080070288241
park d3.080070288241
modified hinchey classification scheme3.080070288241
gastrointestinal symptoms3.080070288241
western dietary pattern3.0717076619745
other immunosuppressive medications3.0717076619745
other diagnoses3.0274001040351
such factors3.0274001040351
other measures3.0274001040351
clinical slide set3.0261714988458
high rate of complications3.0182390421613
heavy use3
avod study group2.9937951655239
low recurrence rates2.9937951655239
potential benefit of antibiotics2.9937951655239
rectal examination2.9622566376653
laparoscopic drainage2.9622566376653
other worrisome features2.9595672453546
normal leukocyte count2.9595672453546
other important confounders2.9595672453546
two recent cross-sectional studies2.9515681170161
patient preference2.9129506302439
ovarian conditions2.9129506302439
urinary symptoms2.9129506302439
actual intake2.9129506302439
several reasons2.9129506302439
western dietary pattern increases2.9027111225923
small peridiverticular abscess2.8944289122796
dietary patterns2.8925076085191
prudent dietary pattern2.8709877393707
one trial2.8502698827718
new theories of disease pathogenesis2.8473146873576
ecological studies2.8284271247462
stool studies2.8284271247462
retrospective studies2.8284271247462
abscess formation2.8173132472613
high likelihood2.8173132472613
kaiser am2.8173132472613
heavy alcohol use2.8039657955522
post-transplant patients2.7831576837137
obese patients2.7831576837137
increased morbidity2.7831576837137
gastrointestinal diseases2.7831576837137
many patients2.7831576837137
adherent patients2.7831576837137
informed patients2.7831576837137
numbers of patients2.7831576837137
proportion of patients2.7831576837137
short-term antibiotic therapy2.7803981823681
clear evidence of inflammation2.766175108537
image-guided percutaneous drainage2.7578805125536
nonstandardized surgical technique2.7494592739972
rectal surgeons guideline2.736580418555
fiber supplements2.7355647997348
fiber supplementation2.7355647997348
medical prevention2.7355647997348
van dieren s2.7322193018926
infectious diseases society of america2.7231572672423
pericolonic inflammatory changes2.7200434229974
nsaid use2.7108060108295
corticosteroid use2.7108060108295
such complications2.7108060108295
regular use2.7108060108295
refractory symptoms2.7108060108295
van randen a2.6960123091946
postoperative intra-abdominal abscess2.6889452937027
such chronic manifestations2.66716827534
moller h. association2.66716827534
rectal surgeons practice parameters2.6617978356723
other racial groups2.6366746651365
segmental colitis2.632148025905
number of episodes2.632148025905
role of immunosuppression2.632148025905
several days2.632148025905
patient stability2.632148025905
west j. role2.6207413942089
concurrent drug use2.6207413942089
adequate medical therapy2.5987138004586
positive predictive values2.5873402367724
high-quality examination2.5755095769014
diver trial2.5755095769014
physical inactivity2.5755095769014
controlled trial2.5755095769014
basic patient information2.5697965868507
useful imaging alternatives2.5697965868507
in-depth patient information2.5697965868507
several adjacent diverticula2.5697965868507
distant abscess2.5457298950218
individual factors2.5457298950218
genetic factors2.5457298950218
morris am2.5457298950218
lisa l. strate2.5327985825943
broad regional dietary habits2.5302513206967
left-sided tenderness2.5148668593659
ct findings2.5148668593659
vigorous physical activity2.4569922134182
readmission rates2.4494897427832
kaiser a2.4494897427832
external validation2.4494897427832
predictors of recurrence2.4494897427832
diverticulitis?clinical presentation2.4494897427832
postsurgical recurrence2.4494897427832
likelihood of diverticulosis2.4494897427832
rectal bleeding2.4322992790978
role of decision-making tools2.401873910352
first-line therapy2.3967817269284
shah r2.3784142300054
greenberg r2.3784142300054
ricciardi r2.3784142300054
boushey r2.3784142300054
lavage group2.3784142300054
austin r2.3784142300054
frago r2.3784142300054
modi r2.3784142300054
pendlimari r2.3784142300054
gregersen r2.3784142300054
hompes r2.3784142300054
erichsen r2.3784142300054
national institute of diabetes2.376176797565
results of laboratory tests2.376176797565
holmer c. outcome of patients2.3593040006382
broad-spectrum antibiotics2.3403473193207
used antibiotics2.3403473193207
low exposure2.3403473193207
recent interest2.3403473193207
overall approach2.3403473193207
jama surg2.3403473193207
laboratory tests2.3403473193207
specific antibiotics2.3403473193207
chronic renal failure2.3299861015014
same hospitalization resection2.3201751253057
hinchey-based classification systems2.3050581003335
medical options2.3003266337912
antibiotic regimens2.3003266337912
current guidelines2.3003266337912
intraoperative factors2.3003266337912
van de wall bj2.2944053808798
body mass index2.2894284851067
complete blood count2.2894284851067
major complications2.2795070569548
dharmarajan s2.2581008643532
spring s2.2581008643532
lee s2.2581008643532
haapaniemi s2.2581008643532
arnold s2.2581008643532
hendren s2.2581008643532
kaneda s2.2581008643532
shaukat a2.2133638394006
mizuki a2.2133638394006
lifestyle interventions2.2133638394006
ben-yehuda a2.2133638394006
aggressive care2.2133638394006
rickenbacher a2.2133638394006
schneider e2.2133638394006
artinyan a2.2133638394006
stroux a2.2133638394006
practice parameters2.2133638394006
wolk a2.2133638394006
heart rate2.2133638394006
gynecologic disorders2.2133638394006
tursi a2.2133638394006
kidney diseases2.2133638394006
chabok a2.2133638394006
fecal peritonitis2.2133638394006
international registry results2.1822472719434
completion of therapy2.165736770668
standard therapy2.165736770668
pericolonic inflammation2.1406951429281
past several decades2.1398263878673
diffuse tenderness2.1147425268811
wasvary h2.1147425268811
recent u.s2.1147425268811
ishii h2.1147425268811
lippert h2.1147425268811
vital signs2.1147425268811
nagata h2.1147425268811
t?nnesen h2.1147425268811
low threshold2.1147425268811
liver function tests2.0757816311124
evidence-based step-up approach2.0757816311124
world gastroenterology organisation2.0757816311124
khatib m2.0597671439071
first time2.0597671439071
blood pressure2.0597671439071
special monitoring2.0597671439071
frank blood2.0597671439071
picchio m2.0597671439071
tatemichi m2.0597671439071
lehmann k2.0597671439071
baron ja2.0597671439071
song m2.0597671439071
millan m2.0597671439071
penna m2.0597671439071
popcorn consumption2.0597671439071
primary care practitioners2.0396489026555
tatme registry collaborative2.0396489026555
right upper quadrant2.0396489026555
ovarian torsion2
practice improvement2
van der wilt gj2
little evidence2
brandimarte g. moderate2
subset analysis2
low-fiber cereals2
left-sided predominance2
clear liquids2
low-quality evidence2
espin e2
appropriate alternative2
multivariable analysis2
young persons2
van gulik tm2
important contributors2
nizri e2
postsurgical morbidity1.9679896712654
major morbidity1.9679896712654
genetic markers1.9679896712654
parthasarathy g1.9343364202677
scheirey c1.9343364202677
mucosal inflammation1.9343364202677
k?ckerling f1.9343364202677
gonzalez-ruiz c1.9343364202677
vallribera f1.9343364202677
wald c1.9343364202677
wynn g1.9343364202677
degree of inflammation1.9343364202677
engholm g1.9343364202677
ault g1.9343364202677
emergency reoperation1.9343364202677
turfah f1.9343364202677
schug-pass c1.9343364202677
oteiza f1.9343364202677
small amounts1.9343364202677
buchli c1.9343364202677
high specificity1.9343364202677
addamo c1.9343364202677
small pouches1.9343364202677
rates of stoma reversal1.9063685859939
separate validation cohorts1.9063685859939
urinary tract infections1.9063685859939
such antispasmodics1.8612097182042
first-line agents1.8612097182042
presence of fecaluria1.8612097182042
two tools1.8612097182042
dairy products1.8612097182042
white persons1.8612097182042
elisei w1.8612097182042
proposed anastomosis1.8612097182042
single agents1.8612097182042
elderly persons1.8612097182042
smalley w1.8612097182042
procedure of choice1.8612097182042
technical review1.8612097182042
shahedi k1.8612097182042
detailed information1.8612097182042
positive effects1.8612097182042
first step1.8612097182042
open-label trials1.8612097182042
scoring nomogram1.8612097182042
broeders ia1.8612097182042
pregnancy test1.8612097182042
professional societies ' recommendations1.8612097182042
beauregard w1.8612097182042
similar results1.8612097182042
subacute onset1.8612097182042
smedh k1.8612097182042
wegdam ja1.8612097182042
benefit of mesalamine1.8612097182042
liu ph1.8612097182042
subsequent advancement1.8612097182042
careful monitoring1.8612097182042
sixth decade of life1.8493111942973
national institutes of health1.8171205928321
ruptured ovarian cyst1.7817974362807
length of hospital stay1.7817974362807
willis dj1.7782794100389
pavia at1.7782794100389
knobben l1.7782794100389
p?hlman l1.7782794100389
associated morbidity1.7782794100389
ahnen dj1.7782794100389
dr. swanson1.7320508075689
diagnostic uncertainty1.7320508075689
of nonaspirin1.7320508075689
baron ej1.7320508075689
overall health1.7320508075689
segal jb1.7320508075689
low?radiation dose protocols1.6983813295649
h?kansson n. smoking1.6983813295649
sophia m. swanson1.6983813295649
fatty dairy foods1.6983813295649
short 4-day course1.6983813295649
peritoneal findings1.6817928305074
liver enzymes1.6817928305074
child-bearing age1.6817928305074
hartmann's procedure1.6817928305074
ewelukwa o1.6817928305074
differential diagnostics1.6817928305074
significant hematochezia1.6817928305074
read t1.6817928305074
university of california1.6817928305074
significant sepsis1.6817928305074
multiple comorbidities1.6817928305074
transanal total mesorectal excision1.6817928305074
asymptomatic diverticulosis1.6817928305074
tsukada n1.6817928305074
ectopic pregnancy1.6817928305074
sanford guide1.6817928305074
h?gel o1.6817928305074
incidental diverticulosis1.6817928305074
symptom resolution1.6817928305074
refined grains1.6817928305074
korte n1.6817928305074
kadro o1.6817928305074
stollman n1.6817928305074
three agents1.6817928305074
postrecovery colonoscopy1.6817928305074
definition of immunosuppression1.6817928305074
aliment pharmacol ther1.5874010519682
receiver-operating characteristic curve1.5874010519682
enough exercise1.5650845800733
avoidance of smoking1.5650845800733
mean time1.5650845800733
gradual advancement1.5650845800733
mortensen lq1.5650845800733
boermeester ma1.5650845800733
respiratory impairment1.5650845800733
geers p1.5650845800733
pedersen jk1.5650845800733
villiger p1.5650845800733
surgeon preference1.5650845800733
jiang jk1.5650845800733
stricture formation1.5650845800733
number of recurrences1.5650845800733
7-day course1.5650845800733
radiation exposure1.5650845800733
hansson le1.5650845800733
white bread1.5650845800733
raptis da1.5650845800733
lehmann ks1.5650845800733
rothenberger da1.5650845800733
oor je1.5650845800733
fecal calprotectin1.5650845800733
single agent1.5650845800733
bradley js1.5650845800733
mazuski je1.5650845800733
fleming km1.5650845800733
kiewiet jj1.5650845800733
reitsma jb1.5650845800733
ritz jp1.5650845800733
rigorous exercise1.5650845800733
eliopoulos gm1.5650845800733
progressive changes1.5650845800733
respiratory compromise1.5650845800733
lake jp1.5650845800733
diagnostic accuracy1.5650845800733
conflicts of interest1.5650845800733
giorgetti gm1.5650845800733
hardiman km1.5650845800733
goldstein ej1.5650845800733
typical manifestations1.5650845800733
schneider eb1.5650845800733
solomkin js1.5650845800733
hunt sr1.5650845800733
atema jj1.5650845800733
steele sr1.5650845800733
stable outpatients1.5650845800733
colovesical fistula1.5650845800733
considerable uncertainty1.5650845800733
stam ma1.5650845800733
professional organizations1.5650845800733
colovaginal fistula1.5650845800733
wheat cl1.4142135623731
buhr hj1.4142135623731
frericks b1.4142135623731
sandler rs1.4142135623731
busch or1.4142135623731
serious events1.4142135623731
21st century1.4142135623731
visceral hypersensitivity1.4142135623731
ultraviolet light1.4142135623731
luminal contrast1.4142135623731
stockmann hb1.4142135623731
madoff rd1.4142135623731
consten ec1.4142135623731
key points1.4142135623731
close attention1.4142135623731
few data1.4142135623731
unnecessary work-ups1.4142135623731
tech coloproctol1.4142135623731
microbial dysbiosis1.4142135623731
good ability1.4142135623731
barrett pr1.4142135623731
pommergaard hc1.4142135623731
chambers hf1.4142135623731
kwaan mr1.4142135623731
result of scarring1.4142135623731
social support1.4142135623731
mental status1.4142135623731
pus aspiration1.4142135623731
roberts pl1.4142135623731
buie wd1.4142135623731
bossuyt pm1.4142135623731
mutch mg1.4142135623731
borao jl1.4142135623731
end colostomy1.4142135623731
familial aggregation1.4142135623731
relevant overview1.4142135623731
regenbogen se1.4142135623731
certain medicines1.4142135623731
birnbaum eh1.4142135623731
maguire lh1.4142135623731
hall jf1.4142135623731
nonconsecutive enrollment1.4142135623731
anaerobic coverage1.4142135623731
interventional radiologist1.4142135623731
loop ileostomy1.4142135623731
permanent stomas1.4142135623731
cooked fruits1.4142135623731
drain placement1.4142135623731
huang es1.4142135623731
spiller rc1.4142135623731
draaisma wa1.4142135623731
bharucha ae1.4142135623731
low-grade fever1.4142135623731
rodvold ka1.4142135623731
san francisco1.4142135623731
oberkofler ce1.4142135623731
reports grants1.4142135623731
passage of gas1.4142135623731
diverticulitis?reported sensitivity1.4142135623731
anorectal stump1.4142135623731
sudden diarrhea1.4142135623731
belzer ge1.4142135623731
frequency of attacks1.4142135623731
hendriks jc1.4142135623731
fleshman jw1.4142135623731
asian populations1.4142135623731
1-year mortality1.4142135623731
tool kit1.4142135623731
green beans1.4142135623731
gilbert dn1.4142135623731
inpatient settings1.4142135623731
rogers aj1.4142135623731
ticarcillin?clavulanic acid1.4142135623731
temporal trends1.4142135623731
involved segments1.4142135623731
main indications1.4142135623731
gaertner wb1.4142135623731
saag ms1.4142135623731
riis ah1.4142135623731
urine sample1.4142135623731
fletcher jg1.4142135623731
extraluminal air1.4142135623731
.0 b013e31821136141
.0 b013e31828545e31
.0 b013e31827324ba1
.0 b013e31820285761

頻出語ITC102

抽出語出現回数 抽出語出現回数 抽出語出現回数
diverticulitis196approach13fistula8
patient148examination13greater8
disease60history13immunocompromised8
risk58incident13large8
not47level13most8
acute41particularly13obstruction8
pain38basis12outpatient8
uncomplicated36intake12quadrant8
study33older12resolution8
antibiotic32several12therapy8
abdominal29severity12age7
abscess29small12antibiotic7
surgery29stage12clinician7
colon28therefore12constipation7
episode28colonoscopy11count7
symptom27drainage11dietary7
complicated26generally11first7
you26lower11inflammation7
also25perforation11information7
diet25they11intravenous7
clinical22use11low-fiber7
diagnosis22when11meat7
imaging22case10more7
other22cause10oral7
bowel21how10presence7
treatment21necessary10red7
complication20often10role7
it20physical10sign7
management20setting1096
recurrence20sigmoid10anti-inflammatory6
recurrent20that10approximately6
factor19-rsb-_NN9consultation6
however19chronic9datum6
such19common9drug6
who18high9emergency6
condition17higher9evaluation6
elective17I9evidence6
what17intervention9fiber6
diverticular16low9gastroenterologist6
trial16mild9immunosuppression6
colonic15more9initial6
guideline15percutaneous9j.gastro6
presentation15prospective9laparoscopic6
severe15usually9leukocyte6
surgical15addition8lifestyle6
year15agent8medical6
diverticulosis14american8most6
inflammatory14cancer8rate6
peritonitis14clear8recently6
resection14colectomy8rectal6

Governor’s Message

 

暑かった夏が終わろうとしています。初夏の頃の欧州の猛暑、インドの豪雨等々の異常気象の夏でもありました。

私にとっても初めての支部長としての暑い夏でした。私の使命の一つとして会員増加を目指す目論見があり(具体的にはまだ明かせませんが)これからさらに力を尽くしていきたいと思っています。会員の増加だけでなく、一旦会員になって頂いた方が会を離れていかれないような魅力作りも必要でしょうし、FACPになる方も増やさなければなりません。

今のところはまだ構想だけですが、会員数がまとまった数になれば地域別に区分けをしてその地域内で活躍されているFACPやMACPの先生方に次の世代の新FACPの推薦をして頂けるシステムを作ったり、地域の組織単位で会員の皆さんとつながりが持てるようになると良いのではないかと考えています。

日本支部はアメリカ大陸以外の支部としては一番最初に出来た支部ですが、その後アジアにはインド、バングラデシュ、東南アジア(現在の支部長担当はシンガポール)、サウジアラビアと支部が出来て現在アジア地区に計5つの支部が存在し、それぞれの支部で支部総会が行われています。これらの支部の支部長とは既に何度かお話をしており、将来アジアの支部合同で合同支部総会や何か催し物ができないかと構想中です。

さらに魅力ある支部にするために会員の皆様のご理解とご協力を頂きながら、さらに前進したいと思います。なにとぞよろしくお願い申し上げます。

2019年夏

前田 賢司

ACP Well-Being Champion Program

ACP日本支部会員の皆様

お世話になっております。牧石徹也と申します。 平素は国際交流委員会で皆様方に大変お世話になっており有難うございます。支部長の前田先生にご推挙頂き、本年4月のACP総会時に2日間のACP Well-Being Championセミナーに参加して参りました。

ACP Well-Being Champion Programとは、世界的に問題となっているPhysicians’ Well-Beingについて対処すべく2018年度から始まったACP本部主催のプログラムです。ACP各支部から1-2名ずつが参加し、丸2日間、この問題への対処法やコーチングについて学ぶ機会を頂き、修了後、各支部にて以下の取り組みを始めるよう指示を受けております。
①まず支部長の支持を得ること
②広く支部内のメンバーに協力を呼びかけ、仲間を集めること
③Mini-Z surveyとよばれる医師向けのアンケートを支部会員全員を対象に実施し、結果についてACP本部と共有すること
④Well-BeingやCoachingについて支部内の意識を高めること
既に前田支部長、支部理事会の先生方にご報告しご支持頂いております。ついては皆様方に是非、Physicians’ Well-Beingに取り組む活動にご協力を頂ければと思いご連絡差し上げた次第です。私などよりずっと以前からこのような活動に取り組んでこられた先生方は多数おいでになると承知しております。そのような方々には是非お力をお貸し頂き 、ご一緒させて頂けましたら幸いです。また、この問題は根が深く、医師のみでは解決しえないことから、果たしてACP支部の活動として対応することが適切なのかというご意見もあろうかと存じます。ただ、私たちの身の回りに日常的に存在する問題であればこそ、できることからやってみるというアプローチもあってよいかと思います。是非、様々なバックグラウンドをお持ちの皆様方のご協力を頂けましたら幸いです。
具体的には、当面の目標としてMini-Z surveyと呼ばれるBurn-outについてのアンケートの実施を考えております。ついては、
①Mini-Z surveyの日本語版の作成にご協力いただける方
②本MLでアンケートを実施する際、survey monkeyなどのツールの利用を考えていますが、そういったことのリテラシーのある方
③今後の活動の進め方について、大所高所から助言やコメントを頂ける方
④本活動に少しでもご興味があり、議論などに加わって頂ける方
もしご協力頂ける方がいらっしゃいましたら牧石まで直接メールにてお知らせ頂けましたら幸いです。今後の活動の進め方については、基本的にメール上で議論させて頂ければと考えております。具体的なご協力のお申し出でなくとも、今後の活動を温かく見守って下さる、今後予定しているアンケ―トにご回答下さるといった形でのご協力も勿論有難く思います。一人で悩みを抱えている医師、医学生に手を差し伸べることができるような活動をできればと思っております。どうぞお力をお貸し下さい。
ACPのwebsiteには医師のBurn-out対策として種々のリソースが提供されています.まだお読みでない方は是非一度ご覧ください.↓
牧石徹也
済生会滋賀県病院腎臓内科
ACP Well-Being Champion 2019

米国での臨床見学プログラムについて

ACP会員の皆様

国際交流プログラム委員会(IEPC)から米国での臨床見学プログラムについてのお知らせです。

日本でも長年臨床教育にたずさわっておられるDr. Herald Stein(スタイン先生)のご厚意により、米国内科学会(ACP)日本支部会員(医師)を対象に,フロリダ大学医学部内科系サブスペシャリティーでの3週間のエクスターンシップ研修の機会を頂きました。本プログラムは昨年に引き続き2年目となります。昨年度は2名の先生にご参加頂き,非常に好評でした(↓ご参加頂いた小尾先生,内山先生のレポートです.是非ご覧ください)。
http://www.acpjapan.org/
(What’s Newコーナーの該当箇所をクリック下さい)

米国のトップレベルの臨床そして教育の現場を肌で感じることのできる貴重な機会です。ご興味をお持ちの先生方は是非ご応募下さい。ただ、今回は募集人数がお一人であり、せっかくご応募頂いても派遣させて頂けるとは限りません。しかし、応募に向けたプロセスそのもの(CVの記載で自身の立ち位置を客観的に眺め、Personal Statementの記載により自身のしたいことを言語化する)も、たとえそれが多くの時間と労力を必要としたとしても、ご応募された方のその後のキャリアパスにとって非常に有益であると思います。是非ご応募をご検討頂ければと幸いです。

派遣に際してはACP会員であることが必要ですが、ご応募時に会員申請頂ければ大丈夫ですので、先生方の身の回りにご興味がおありの先生がおられれば是非ご共有頂けましたら幸いです。
何卒宜しくお願い致します。

米国内科学会(ACP)日本支部
国際交流委員会(IEPC)

下記が募集要項となります。

========================================================
ACP日本支部 国際交流プログラム委員会(IEPC)主催
臨床見学プログラム2019 -2020

米国フロリダ州のUniversity of Florida, Department of Medicineの内科系専門科で,3週間のエクスターン研修ができます。現地でのプログラムを監修頂くのは日本でも長い指導歴をお持ちのDr. Jerald Stein(スタイン先生)です。米国の一流の内科系臨床研修プログラムを見学できる貴重な機会であり、将来米国での臨床研修を考えている若手医師、米国式臨床研修システムを日々の指導に取り入れたいと考えている指導医クラス、そして米国の臨床研修システムを肌で感じてみたい全ての方に最適です。当委員会メンバーが研修前から研修者をサポートします。

なお、このプログラムはACP日本支部とフロリダ大学医学部との契約に基づくものではなく、あくまでスタイン先生の「25年間の日本での指導を通じて得た友情に対する感謝の気持ち」として先生のご厚意によりACP日本支部会員へ提供されるものです。そのため、スタイン先生およびフロリダ大学医学部や見学科に対しての費用は発生しません。
(具体的には、スタイン先生は見学希望科の調整と、見学希望科のFacultyに参加者のメンターとなって頂く調整をして下さいます。)

スタイン先生の日本でのご活動については下記URLをご覧下さい。
http://plaza.ufl.edu/jerrydoc

見学の時期:2020年4月もしくは5月(研修先と日程を調整し決定します)
見学の期間:3週間
研修内容:エクスターン研修(基本的に見学のみとなります)
研修可能診療科:内科系診療各科(Hospital Medicine, Nephrology, Infectious disease, Rheumatology, Emergency Medicine, etc. )参加者が見学を希望する科に対してスタイン先生が直接交渉し調整されます。必ずしも希望する科を見学できる保証はありません。
応募締め切り:2019年9月17日午後5時
派遣人数:1名
参加費用:飛行機代、現地滞在費、現地生活費は自己負担となります。研修先への費用はありません。
現地での病気やけが等:自己の責任の下,対応頂くことになります.

応募資格・要件:
(1) ACP会員であること
(2) 卒業後2~5年程度
(3) 一般的なコミュニケーション英語能力、医療英語能力がある方
(4) 米国での臨床研修に目的意識を持って、意欲的に取り組んでいる方
(5) 研修後、ACP日本支部での活動に積極的にご協力頂ける意志がある方
(6) 渡米中の3週間は、毎週末、国際交流委員会へ研修内容をメールにてご報告頂くこと。臨床見学終了後は日本語でA4 1-2枚程度、英語で 500 -1000words程度の体験記をご提出頂くこと。

応募書類:
(1) Curriculum vitae (CV) (英語で記載. Dr. Steinはもちろん、訪問先へも提出する可能性があります)
(2) Personal Statement(PS) (英語で記載. Dr. Steinはもちろん、訪問先へも提出する可能性があります)
(3) TOEFL(iBT)、IELTSなどの英語検定試験のスコアのコピー(任意)
(4) USMLE step1、step2 CKの合格者はそのscore reportのコピー、step2 CSの合格者は合格証のコピー、ECFMG certificate保持者はそのコピー(任意)
(5) ACP日本支部会員の確認書会員番号、会員の種類(member, associate member, fellowなど)を記載して提出してください。現在会員でない方は、応募時に会員申請頂ければ応募可能です。

応募方法:上記必要書類(PDF等のデジタルファイルにしたもの)を添付の上、下記宛にお送りください。
ACP日本支部事務局 office@acpjapan.org

選考方法:当委員会にて書類審査 。その後、書類審査通過者に対しIEPC委員による直接面談もしくは電話・スカイプなどによる面接。

選考基準:
本プログラムでの学びを日本国内の医療向上に還元しようとする気持ちの強さ,ならびに英語力。(先方の意向により,本プログラムを米国臨床留学の直接の足掛かりとすることはご遠慮下さい。具体的には、参加中に懇意になった米国人医師に推薦状(LoR)の記載をお願いする等の行為は望ましくありません。将来的な臨床留学の意思そのものを否定するものではありません。)

選考結果:書類選考結果については募集締切り後2週間以内に応募者本人へEmailにて通知します。面接に進まれる方とは、改めて面接の日時や方法等を調整します。

一般社団法人米国内科学会日本支部事務局
〒162-0833 東京都新宿区箪笥町43 新神楽坂ビル2階
有限会社ビジョンブリッジ内

E-mail:office@acpjapan.org
http://www.acpjapan.org

プログラム担当:
ACP日本支部国際交流プログラム委員会(IEPC)
========================================================

2019年 ACPJC 年次総会講演会における学生企画の御報告

Student Committee委員よりACP年次総会・講演会のご報告をいただきました。ご報告させていただきます。(PRC委員 宮内隆政)

 

ACP日本支部の皆様

ACP日本支部年次総会・講演会2019の1日目
6月8日(土) 14時20分~15時40分に開催されました
Student Committee企画「夢見る海外臨床講座」
について御報告させて頂きます。

本企画は、ACPを学生へ広報する目的として、
また海外臨床に興味のある学生の交流の場として、
Student Committeeメンバーが一から企画準備したものです。

企画の内容は、
海外臨床に思いを馳せる3つのチームによるプレゼン合戦で、
・USMLEを中心とした海外臨床留学までの道のりについての紹介
・有名な海外医療ドラマをもとに臨床現場を考える検討会
・実際のCaseをもとにした本格的な症例検討会
といった、それぞれのチーム色のある、大変活気のあるものとなりました。

それぞれの発表では、同時にクイズの出題やディスカッションの時間があり、
最もクイズの正解やディスカッションに貢献した学生の表彰も行われました。

30名を越える参加者には、医学生だけでなく、多くの先生方もいらっしゃいました。
症例ディスカッションの時間では、学生が苦戦する中、
非常に鋭い発言をして頂き、ディスカッションを非常に盛り上げて下さいました。

本企画は学生が一から企画準備したものでしたが、
当日も含め、ACP日本支部に所属する多くの先生方のご支援の御陰で実現することができました。
本企画に関わって下さいました全ての方への御礼の言葉を最後に御報告とさせて頂きます。
誠にありがとうございました。

ACP日本支部 Student Committee 委員長
平井智大

——

Student Committee Event Report

The Student Committee held a program for student exchange at the ACPJC annual meeting 2019.
The program consisted of three presentations and the discussions were very exciting. More than 30 participants attended.
We thank everyone who helped make this program possible.

ACPJC Student Committee Chair
Tomohiro Hirai

Report my experience in the externship at the Department of Hospital Medicine in Shands Hospital, UF Health

Tokyo Bay Urayasu Ichikawa Medical Center General Internal Medicine Resident

Shuhei Uchiyama

I am honored to report my experience in the externship at the Department of Hospital Medicine in Shands Hospital, UF Health, a program by the International Exchange Program Committee of ACP Japan Chapter.

I applied to this program because I would like to be a resident in the U.S., and to become a specialist in hospital medicine in the future. Since the field is not yet common in Japan, I thought that I would be able to gain a lot of experience that could not be obtained in my country. Consequently, my guess was correct.

I observed two branches of the division; the floor team and the consultation team. The floor team basically takes care of inpatients who have multiple health problems not limited to one organ. In my hospital, I usually work as a general internal medicine doctor, and I noticed that there is not such a big difference in terms of work content and treatment strategy between U.S. and Japan. I was pleased to know that the clinical skills that I have gained in my workplace are as good as the ones residents of one of the best teaching hospitals in the U.S. can learn.

The consultation team consists of a resident and an attending doctor. They accept consultations from other departments and procedures including thoracentesis, paracentesis, lumbar puncture, and so on. The main cases of referrals are co-management of patients in surgery divisions. For example, we get many patients from orthopedics with comorbidities such as hypertension, diabetes, and heart failure. The cooperation between each department to treat patients was quite impressive.

Since this unique consultation system is the biggest reason for me to become a hospitalist in the U.S., I was happy to have the chance to observe their work. Though the system is not prevalent in my country, I am convinced that it is beneficial to both patients and doctors in other departments because surgeons do not have to take care of those problems and can concentrate on their specialties, and patients are treated by specialists of internal medicine. In the future, I would like to learn about this culture and bring it back to my country to make the Japanese healthcare system better.

Not only was it an excellent chance to learn about medicine in America, but it was also such a great opportunity for me in terms of my future carrier as a resident. Doctor Kattan, the attending doctor, was so generous that he allowed me to see patients and make presentations on each round. Although it was a short externship, I felt that I made a significant improvement in my clinical skills through this experience. I believe that it was achieved by reflecting on the attending doctor’s evaluation and advice about my assessments, plans, and presentations every day. He also asked me a lot of clinical questions related to patients during rounds, which revealed that I need to be more familiar with a wide variety of diseases, treatments, etc. I also realized that it was vital for me to acquire his ability to educate residents and medical students in the future.

Through this externship, my determination of becoming a hospitalist has only gotten deeper. I strongly recommend this program to those who wish to work in the United States.

Finally, I would like to express my heartfelt gratitude to the attending doctors who gave us the chance to join the externship, doctors in IECP of ACP Japan Chapter including Dr. Maliishi, and Dr. Stein who kindly and wholly helped me before and during my stay in Gainesville, Florida.

University of Florida Department of Hospital Medicineでのエクスターンシップ

東京ベイ・浦安市川医療センター 総合内科専攻医

内山 秀平

このたび、アメリカ内科学会日本支部国際交流委員会のプログラムにより、University of Florida Department of Hospital Medicineに3週間のエクスターンシップの機会を頂きました。学んだことはあまりに多く、書ききれない事柄も多々ありますが、できるだけ詳細にご報告させていただきます。

はじめに、今回ローテーションさせていただきましたDepartment of Hospital Medicineとその志望理由について説明いたします。この診療科はいわゆるHospitalistが勤務している診療科であり、入院中の患者のうち複数科にわたるプロブレムを持つ患者を中心に担当を行っています。また、他科(主に整形外科、泌尿器科、産婦人科などの非内科系診療科)からの内科的コンサルトも引き受けています。私は将来米国にてHospital Medicineを専攻したいと考えており、今回のエクスターンシップは本場のHospital Medicineを学ぶまたとない好機と考えたため、応募をさせていただきました。

Hospitalistの勤務体系はseven days on, seven days offと呼ばれており、7日間の連続勤務ののちに7日間の休暇があります。休暇に入ってしまう関係上、単独の医師をShadowしつづけることができないため、7日間をFloorでshadowしたのち、次の7日間をConsultation serviceで過ごすという方法を採らせていただきました。正確には週の中盤でseven daysの交替が行われるため、バランスよくいずれも1週間半ずつ滞在することができました。

①Floor

こちらは入院患者を担当医として受け持つ部門です。アメリカでは年度が終わりかけている時期だったこともあり、attendingの医師が一人で担当を行っており、そちらを見学させていただきました。

入院患者の疾患は多岐にわたり、心不全、肺炎、COPD急性増悪、蜂窩織炎などの日本でも比較的よくみられる疾患から、cystic fibrosis、sickle cell diseaseによるacute chest syndrome、cocaine-induced ACSなどの米国ならでは(?)の症例まで見学をすることができました。日本でも見られる疾患の診療内容に関しては普段から私が総合内科医として行っているものと大きな差はないと感じられましたが、コストの意識が強い影響か退院のスピードは非常に早く、case managerが各患者のdispositionについて毎日確認を行っている場面が非常に印象的でした。

②Consultation service

こちらは他科からのコンサルトを受ける部門です。PGY-3のresidentとattendingの医師がチームを組んでおり、そこにお邪魔する形で参加させていただきました。

主な診療内容としては外科病棟入院中の患者の内科的”comanagement”(「併診」という単語が最も近いかもしれません)や心不全管理、高血圧緊急症などがありました。さらに院内で腹腔穿刺、腰椎穿刺、中心静脈カテーテル留置などの処置が必要になった場合のコンサルト先もこちらでした。

もともと私がhospital medicineに興味を持ち始めたのは総合内科としての病棟担当もさることながら、このような他科からのcomanagementのシステムが素晴らしいと考えたことが契機でした。例としては、大腿骨頸部骨折で手術を控えている患者の併存疾患である高血圧、糖尿病、心不全のマネジメントを受け持つ、というような内容です。コンサルテーションのみを受け持つ部門は日本の病院には一般的でないと思われますが、非常にやりがいのある仕事だと感じられました。

さらに、attendingであるDr. Kattanは私がECFMG certificate holder(=USMLE STEP1/2 CK/2 CSをクリア済)であること、米国でresidencyを行おうと考えていることを汲んでくださり、患者のプレラウンドから回診におけるプレゼンテーション、さらには処置まで許可をいただくことができました。加えて短時間ではありますが新規のコンサルテーションがあると最初に通知が来るPager(ポケベル)も渡していただき、実に多くのことを経験させていただきました。これらの経験は私の将来のキャリアにおいてかけがえのないものになると確信しています。

今回のエクスターンシップでは本場米国のHospitalistの診療内容を深く知ることができただけでなく、私自身のキャリアにおいても大きな一助となったと感じております。学んだ多くのことを胸に、これからも将来に向けて挑戦し続けていく所存です。

最後に、このような貴重な機会を頂きました牧石先生をはじめ国際交流委員会の先生方、滞在前だけでなく現地にて多くのアドバイス、日常の手助けを頂きましたDr. Steinに心からの感謝を申し上げ、ご報告とさせていただきます。